There is increasing interest in using treatment breaks to reduce side effects without affecting outcomes. This phase 3 trial (STAR) was designed to see how a break in tyrosine kinase inhibitor (TKI) treatment compared to standard first-line treatment with TKIs for people with advanced renal cell carcinoma (RCC). Overall survival time and economic evaluation (quality […]
There is very little information on the effectiveness of sunitinib (a vascular endothelial growth factor (VEGF) inhibitor) as a second-line treatment after first-line treatment with immunotherapy for patients with metastatic renal cell carcinoma (RCC). A study published in Clinical Genitourinary Cancer last month looked at 102 patients in a real-world setting who were treated with […]
To date, a reliable biomarker is yet to be discovered for the response of kidney cancer patients to treatment or for prognosis. In this review paper, Dr Robert Motzer and his research group from Memorial Sloan Kettering in the USA identified a set of 26 genes whose activity correlated with progression-free survival in the combination […]
A recent study published in Clinical Genitourinary Cancer has found that the use of first-line sunitinib did not have any influence on the effectiveness of second-line immunotherapy for patients with metastatic renal cell carcinoma (RCC). The researchers found no statistically significant association between the duration of the use of first-line sunitinib and clinical outcomes with […]
An analysis of the data collected during the S-TRAC study, in which patients with high-risk, localised renal cell carcinoma (RCC) were treated with adjuvant sunitinib (after surgery), showed that sunitinib improved disease-free survival over placebo, but not overall survival. Researchers decided to look at biomarkers for disease-free survival in this study. In this study, a […]
A study published in Clinical Genitourinary Cancer looks at the treatment of patients with metastatic RCC with sunitinib after they have already been treated with sunitinib and have stopped responding. Sunitinib is the standard of care for patients with metastatic RCC. However, nearly all patients will eventually stop responding to treatment with sunitinib and develop […]
The US Food and Drug Administration (FDA) has designated ilixadencel a Regenerative Medicine Advanced Therapy (RMAT) as a treatment for metastatic renal cell carcinoma (RCC). This designation is similar to the FDA’s Breakthrough Therapy Designation, and recognises the therapeutic potential of ilixadencel as well as the unmet patient need for viable therapies for this difficult-to-treat […]
This study describes patient-reported outcomes from the phase 3 IMmotion151 study to assess the safety and efficacy of atezolizumab in combination with bevacizumab in patients with untreated metastatic renal cell carcinoma (RCC) and who were positive for the PD-L1 biomarker. In this study, the patients treated with atezolizumab plus bevacizumab had longer progression-free survival compared […]
A recent post hoc analysis of the results from the COMPARZ clinical trial, which compared first-line treatment with pazopanib versus sunitinib for metastatic renal cell carcinoma (RCC), was published in Clinical Genitourinary Cancer last February 2020. During the COMPARZ study, pazopanib and sunitinib (VEGF-TKI targeted therapy) had similar efficacy. However, this analysis showed that the […]
Results from a recent phase 2 clinical trial of ilixadencel plus sunitinib for the treatment of newly-diagnosed metastatic renal cell carcinoma (RCC) were presented at the 2020 American Society of Clinical Oncology (ASCO)/Society for Immunotherapy of cancer (SITC) Clinical Immuno-Oncology Symposium, in Orlando, Florida, in February. Ilixadencel is an immune primer designed to increase the body’s […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
